NEWSTIER

Fri, Aug 28
Status: JUNE AliveWelcome: Visitordata 8s old

Latest Headlines

808 categorized of 2020
DOW_JONES23:574h agobearish

U.S. to Take Control of Much of Venezuela's Proven Oil Reserves -- WSJ

U.S. to Take Control of Much of Venezuela's Proven Oil Reserves -- WSJ | President Trump confirmed late Friday that the U.S. reached a deal with Venezuela to secure control of a big chunk of the Latin American country's oil reserves. "At my direction, Secretary of State Marco Rubio, and Secretary o…
DOW_JONES23:554h ago

Review & Preview: Warsh Gets Real on Inflation -- Barrons.com

Review & Preview: Warsh Gets Real on Inflation -- Barrons.com | Alex Eule Warsh's Reality. In his first Jackson Hole speech as chairman of the Federal Reserve, Kevin Warsh reminded the market that he isn't just paying lip service to rising prices. Warsh called out "65 months of sustained, elevated…
MACRO & CENTRAL BANKS / INFLATION/CPI
DOW_JONES23:524h ago

A Sneaker Apocalypse -- Barrons.com

A Sneaker Apocalypse -- Barrons.com | Dick's Sporting Goods has a sneaker problem and footwear stocks are feeling the pinch. Shares of the sporting goods retailer fell more than 25% after reporting second-quarter earnings, its largest percentage decrease on record, according to Dow Jones Market Dat…
DOW_JONES23:464h agobullish

13D Filings -- Barrons.com

13D Filings -- Barrons.com | These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filing…
BENZINGA23:454h ago

$100 Invested In Illumina 20 Years Ago Would Be Worth This Much Today

$100 Invested In Illumina 20 Years Ago Would Be Worth This Much Today | 7:45 PM EDT, August 28, 2026 (Benzinga Newswire) Illumina (NASDAQ:ILMN) has outperformed the market over the past 20 years by 4.32% on an annualized basis producing an average annual return of 13.55%. Currently, Illumina has a…
BENZINGA23:304h ago

$1000 Invested In Acuity 20 Years Ago Would Be Worth This Much Today

$1000 Invested In Acuity 20 Years Ago Would Be Worth This Much Today | 7:30 PM EDT, August 28, 2026 (Benzinga Newswire) Acuity (NYSE:AYI) has outperformed the market over the past 20 years by 1.38% on an annualized basis producing an average annual return of 10.6%. Currently, Acuity has a market ca…
DOW_JONES23:304h agobullish

Press Release: INTURAI VENTURES ANNOUNCES CLOSING OF FIRST TRANCHE OF PRIVATE PLACEMENT

Press Release: INTURAI VENTURES ANNOUNCES CLOSING OF FIRST TRANCHE OF PRIVATE PLACEMENT | (CSE: URAI / OTC: URAIF / FSE: 3QG0) investor@inturai.com Highlights -- The Company has completed the first tranche of its previously announced non-brokered private placement, issuing 6,273,331 Units at a pric…
CAPITAL RAISING / PRIVATE PLACEMENT
ACCESSWIRE23:304h agobullish

IP Strategy Receives Nasdaq Notification Regarding Delayed Form 10-Q Filing

IP Strategy Receives Nasdaq Notification Regarding Delayed Form 10-Q Filing | GIG HARBOR, WA / ACCESS Newswire / August 28, 2026 / IP Strategy Holdings, Inc. (Nasdaq:IPST) (the "Company" or "IP Strategy") today announced that it received a notification letter from The Nasdaq Stock Market LLC ("Nasd…
PR_NEWS_WIRE23:304h agobullish

INTURAI VENTURES ANNOUNCES CLOSING OF FIRST TRANCHE OF PRIVATE PLACEMENT

INTURAI VENTURES ANNOUNCES CLOSING OF FIRST TRANCHE OF PRIVATE PLACEMENT | (CSE: URAI / OTC: URAIF / FSE: 3QG0) investor@inturai.com Highlights The Company has completed the first tranche of its previously announced non-brokered private placement, issuing 6,273,331 Units at a price of $0.15 per Uni…
CAPITAL RAISING / PRIVATE PLACEMENT
DOW_JONES23:024h agobullish

Takeda's Mimrylo Gets FDA Approval to Treat Blood Cancer Condition

Takeda's Mimrylo Gets FDA Approval to Treat Blood Cancer Condition | Takeda's treatment for erythrocytosis in adults with polycythemia vera, a form of blood cancer, received approval from the Food and Drug Administration. The company said Friday that the FDA approved its new drug application for Mi…
REGULATORY & CLINICAL / FDA/APPROVAL
ACCESSWIRE23:004h agobullish

Lobe Sciences Ltd. Announces Upsize to Non-Brokered Private Placement

Lobe Sciences Ltd. Announces Upsize to Non-Brokered Private Placement | NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / August 28, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE),…
CAPITAL RAISING / PRIVATE PLACEMENT
MIDNIGHT_TRADER22:594h ago

CVC-Backed Home Insurer Bamboo Files For US IPO

CVC-Backed Home Insurer Bamboo Files For US IPO | 06:59 PM EDT, 08/28/2026 (MT Newswires) -- Bamboo Insurance Services, a home insurance company controlled by private equity firm CVC Capital Partners, filed for a US initial public offering that will allow existing shareholders to sell stakes, Bloom…
CAPITAL RAISING / IPO
MIDNIGHT_TRADER22:485h ago

Market Chatter: NIKE Hires Former Foot Locker Executive To Run Converse Operations

Market Chatter: NIKE Hires Former Foot Locker Executive To Run Converse Operations | 06:48 PM EDT, 08/28/2026 (MT Newswires) -- NIKE (NKE) named former Foot Locker executive Kristin Bauer as chief operating officer of its struggling Converse brand, effective Sept. 14, Bloomberg News reported, citin…
ECONOMY & JOBS / HIRING
ACCESSWIRE22:455h agobullish

KEO Energy Enters Into Operating Agreements in Venezuela with PDVSA

KEO Energy Enters Into Operating Agreements in Venezuela with PDVSA | STOCKHOLM, SE / ACCESS Newswire / August 28, 2026 / KEO Capital AB (publ) ("KEO Capital" or the "Company") (Nasdaq Stockholm:KEOC) announces that, following approval of its board of directors, Maha Energy Indiana, Inc. ("Maha Ind…
BUSINESS_WIRE22:405h ago

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera | MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV) MIMRYLO…
REGULATORY & CLINICAL / FDA/APPROVAL